drugset / Trial / NCT01769391

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

NCT01769391

Phase 2 Completed 167 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.

Timeline

Start
2013-01
Primary completion
2015-04
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Necitumumab Monoclonal antibody 800 mg Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous